Penumbra (PEN) Income from Continuing Operations (2014 - 2026)
Penumbra (PEN) posted quarterly Income from Continuing Operations of 34787000.0 for Q2 2026, down 23.16% year-over-year from 45270000.0 in Q2 2025, and up 6.76% quarter-over-quarter from 32584000.0 in Q1 2026.
Penumbra (PEN) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Penumbra (PEN) has reported Income from Continuing Operations for 13 consecutive years, with 34787000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income from Continuing Operations fell 23.16% year-over-year to 34787000.0; the TTM figure through Jun 2026 stood at 160539000.0 (up 8.73% YoY), while the FY2025 annual figure was 177687000.0, up 1168.11% from the prior year.
- Income from Continuing Operations improved to 34787000.0 in Q2 2026 per PEN's latest filing, from 32584000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 54218000.0 in Q4 2023 and bottomed at 60174000.0 in Q2 2024.
- Historically, Income from Continuing Operations has averaged 19329333.33 across 5 years, with a median of 24207000.0 in 2023.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations jumped 10725.32% — and 2024, when it sank 417.78%.
- Penumbra's Income from Continuing Operations stood at 3877000.0 in 2022, then soared by 1298.45% to 54218000.0 in 2023, then plunged by 37.88% to 33682000.0 in 2024, then jumped by 40.56% to 47343000.0 in 2025, then dropped by 26.52% to 34787000.0 in 2026.
- Business Quant data shows PEN's Income from Continuing Operations at 34787000.0 in Q2 2026, 32584000.0 in Q1 2026, and 47343000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.20 Bn | 194.60 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 129.69 Bn | 126.21 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 120.14 Bn | 110.92 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 74.16 Bn | 73.62 Bn | 3.85 Bn | 905.00 Mn |
| 5 | Edwards Lifesciences | 52.68 Bn | 48.43 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.57 Bn | 32.62 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 34.09 Bn | 31.98 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.49 Bn | 23.17 Bn | 4.55 Bn | 1.04 Bn |
| 9 | Steris | 23.19 Bn | 22.70 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Penumbra | 12.81 Bn | 12.15 Bn | 264.94 Mn | 34.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.79 Mn |
| Mar 31, 2026 | 32.59 Mn |
| Dec 31, 2025 | 47.34 Mn |
| Sep 30, 2025 | 45.85 Mn |
| Jun 30, 2025 | 45.31 Mn |
| Mar 31, 2025 | 39.22 Mn |
| Dec 31, 2024 | 33.68 Mn |
| Sep 30, 2024 | 29.48 Mn |
| Jun 30, 2024 | -60.20 Mn |
| Mar 31, 2024 | 11.00 Mn |
| Dec 31, 2023 | 54.22 Mn |
| Sep 30, 2023 | 9.21 Mn |
| Jun 30, 2023 | 18.94 Mn |
| Mar 31, 2023 | 8.56 Mn |
| Dec 31, 2022 | 3.88 Mn |
| Sep 30, 2022 | -2.27 Mn |
| Jun 30, 2022 | -3.69 Mn |
| Mar 31, 2022 | 79,000.00 |
| Dec 31, 2021 | -24.63 Mn |
| Sep 30, 2021 | 8.03 Mn |